semaglutide news oct 26 2025 The FDA has approved the first GLP-1 pill for weight loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day Wegovy tablet, is also approved for reducing cardiovascular Weight-loss drug tied to lower

April 2025: Novo Nordisk committed USD 1.09 billion to expand Montes Claros fill-finish capacity, with operations slated for late 2026

Semaglutide begins its biological action almost immediately after injection, as it circulates through your bloodstream and binds to GLP-1 receptors throughout your digestive tract and brain

A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus

Genomic DNA, cDNA, and deduced amino acid sequence

Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons

It's important to note that whilst Ozempic is licensed specifically for type 2 diabetes, a higher-dose formulation of semaglutide (Wegovy) has been approved by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities